CUE
Cue Biopharma, Inc.NASDAQHealthcare$0.18-1.61%ClosedMarket Cap: $14.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.72
P/S
0.51
EV/EBITDA
0.39
DCF Value
$-8.87
FCF Yield
-156.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.0%
Operating Margin
-96.6%
Net Margin
-96.9%
ROE
-165.2%
ROA
-63.0%
ROIC
-86.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $21.9M | 85.4% | $2.0M | $1.6M | $0.01 | — |
| FY 2025 | $27.5M | 87.3% | $-26.6M | $-26.6M | $-0.28 | — |
| Q3 2025 | $2.1M | 96.3% | $-7.5M | $-7.4M | $-0.07 | — |
| Q2 2025 | $3.0M | 100.0% | $-8.6M | $-8.5M | $-0.09 | — |
| Q1 2025 | $421.0K | 100.0% | $-12.3M | $-12.3M | $-0.17 | — |
| Q4 2024 | $1.6M | 100.0% | $-9.6M | $-9.5M | $-0.13 | — |
| FY 2024 | $9.3M | 100.0% | $-41.5M | $-40.7M | $-0.72 | — |
| Q3 2024 | $3.3M | 100.0% | $-8.8M | $-8.7M | $-0.17 | — |
| Q2 2024 | $2.7M | 100.0% | $-10.4M | $-10.2M | $-0.20 | — |
| Q1 2024 | $1.7M | 100.0% | $-12.7M | $-12.3M | $-0.25 | — |
| Q4 2023 | $1.8M | -640.6% | $-13.8M | $-13.4M | $-0.28 | — |
| FY 2023 | $5.5M | -593.9% | $-52.1M | $-50.7M | $-1.11 | — |